Bosh sahifaNVAX • NASDAQ
add
Novavax Inc
7,45 $
Seans yopilganidan keyin:(0,39%)-0,029
7,42 $
Yopilgan:6-iyn, 19:59:00 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
6,99 $
Kunlik diapazon
7,02 $ - 7,48 $
Yillik diapazon
5,01 $ - 19,50 $
Bozor kapitalizatsiyasi
1,21 mlrd USD
Oʻrtacha hajm
11,69 mln
Narx/foyda
2,79
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 666,66 mln | 610,30% |
Joriy xarajat | 47,59 mln | -42,17% |
Sof foyda | 518,65 mln | 451,51% |
Sof foyda marjasi | 77,80 | 149,49% |
Har bir ulushga tushum | 2,93 | 379,05% |
EBITDA | 524,35 mln | 514,23% |
Amaldagi soliq stavkasi | 0,23% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 731,48 mln | 52,21% |
Jami aktivlari | 1,29 mlrd | -4,47% |
Jami passivlari | 1,37 mlrd | -38,37% |
Umumiy kapital | -75,64 mln | — |
Tarqatilgan aksiyalar | 161,97 mln | — |
Narxi/balansdagi bahosi | -14,87 | — |
Aktivlardan daromad | 90,42% | — |
Kapitaldan daromad | -1 244,28% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 518,65 mln | 451,51% |
Operatsiyalardan naqd pul | -185,50 mln | -122,01% |
Sarmoyadan naqd pul | -73,32 mln | -911,30% |
Moliyadan naqd pul | -7,06 mln | -219,96% |
Naqd pulning sof oʻzgarishi | -266,81 mln | -203,63% |
Boʻsh pul | -315,38 mln | 42,96% |
Haqida
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
Tashkil etilgan
1987
Sayt
Xodimlar soni
952
